BICO Group AB (publ) (BCCOY) Q1 2026 Earnings Call Transcript

BICO Group reported 11% organic growth in Q1 2026, but reported growth was -1.4% due to currency headwinds. EBITDA was -SEK 42 million and adjusted EBITDA was -SEK 11 million, with SEK 52 million of restructuring costs weighing on results; operating cash flow was positive at SEK 47 million. The company also issued EUR 40 million of senior secured bonds, strengthening liquidity to support growth and navigate ongoing uncertainty.

Analysis

The cleanest read-through is not on the reported growth itself, but on capital structure optionality: by taking on secured debt while still generating positive operating cash flow, management is effectively buying time for the demand cycle to normalize without being forced into dilutive equity. That tends to favor a narrower set of vendors with mission-critical consumables, service contracts, and higher switching costs, while smaller toolmakers and distributors exposed to academic budgets remain vulnerable to share loss if procurement stays weak for another 2-3 quarters.

The biggest second-order effect is on pricing discipline across the lab automation stack. A company that can finance through the trough and keep investing in product cadence can pressure peers that rely on equity markets or short-duration bank lines, especially in Europe where refinancing risk is still repriced aggressively. If the sector stabilizes, the first beneficiaries are usually the platforms with installed bases and recurring revenue, not the thesis-heavy emerging names that need fresh labs to open.

The key risk is that the bond issuance is being read as reassurance when it may actually be a sign that management wants a runway ahead of a slower-than-expected recovery. If U.S. academic funding remains soft into the summer grant season, the revenue bridge can widen before it narrows, and leverage optics become more important than absolute liquidity. In that scenario, any near-term rally in the stock could fade within weeks if gross margin or order intake disappoints again.

The contrarian angle is that the market may be underestimating how much a modest demand inflection matters once restructuring is largely done. With cost actions already absorbed, even a low-to-mid single-digit improvement in organic growth can translate into a disproportionate rebound in EBITDA over the next 2-4 quarters. That makes this a classic quality-vs-distressed inflection setup: if recovery is real, the equity can rerate quickly; if not, the debt instrument should still outperform the stock on a risk-adjusted basis.

Key Decisions for Investors

• Favor a relative-value long basket of higher-quality lab tools/automation names versus weaker, grant-exposed peers over the next 3-6 months; the best risk/reward sits in names with recurring revenue and strong balance sheets that can take share if funding stays choppy.
• Avoid chasing an outright long in the equity until the next order-intake or margin print confirms that organic growth is sustainable; the setup is more likely to produce sharp 10-20% pullbacks on any macro disappointment than a straight-line rerating.
• Consider a long-bond/short-equity expression if the securities are accessible: the secured notes should have a better downside cushion than the common if recovery remains uneven over the next 6-12 months.
• If the stock rallies 15%+ on financing relief without a corresponding improvement in demand indicators, fade it tactically with a short/put overlay; the market may be pricing liquidity solved when the real issue is still end-demand timing.
• Watch for a catalyst trade into the next two quarters: if U.S. academic budgets improve or management reiterates sustained organic growth, a medium-term call spread can capture rerating with limited downside versus common stock.